VRX


DEALS AND RUMORS OF DEALS DOMINATED THIS WEEK IN HEALTHCARE

This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …

Canaccord Reiterats Positive Outlook On Valeant Pharmaceuticals Following Salix Deal

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) received another set of praises today from analyst Neil Maruoka of Canaccord Genuity in a research report released today. The report comes …

Cantor Raises Valeant Pharmaceuticals Price Target Following Acquisition Of Salix Pharmaceuticals

In a research report published Monday, Cantor analyst Irina Rivkind maintained a Buy rating on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and raised the price target to $214, …

Analysts Make Bullish Ratings in Response to Valeant’s Increased 2015 Guidance

Valeant Pharmaceuticals (NYSE: VRX) held a conference call with investors on Thursday, January 8th, in which the company increased its guidance for 2015. Initially, …

Ackman’s Pershing Group Buys Stake in Zoetis

Zoetis, Inc. (NYSE: ZTS) is an animal health company that produces vaccines for pets and livestock.

Actavis Says ‘Let’s Make A Deal’

I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …

Cantor Maintains Buy On Valeant Following 3Q14 Results; Raises PT $182

In a research report issued Tuesday, Cantor analyst Irina Rivkind maintained a Buy rating on Valeant Pharmaceuticals (NYSE:VRX) and raised his price target to $182 …

Canaccord Genuity Maintains Buy On Valeant Pharmaceuticals, $168 PT

In a research report issued today, Canaccord Genuity analyst Neil Maruoka maintained a Buy rating on Valeant Pharmaceuticals (NYSE:VRX) with a price target of …

A Bizarre Pharma Love Triangle

Back on July 3rd of this year, I wrote about a good find in pharma called Salix Pharmaceuticals (NASDAQ:SLXP). Salix Pharmaceuticals is a …

Cantor Fitzergald Reiterates Buy On Valeant Pharmaceuticals Following Examination Of Key AGN Deal Issues

In a report issued today, Cantor Fitzergald analyst Irina Rivkind reiterated a Buy rating on Valeant Pharmaceuticals International (NYSE:VRX) with a $167 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts